ReviewSeminars in immunopathology2007
The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation.
Review in Seminars in immunopathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 139 citations in OpenAlex.
- Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.Journal of gastroenterology · 2025Review
- Direct RNA sequencing reveals chicken post-transcriptional modifications in response to Campylobacter jejuni inoculation.BMC genomics · 2025Article
- NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals.Frontiers in pharmacology · 2025Review
- Unexpected regulatory functions of cyprinid Viperin on inflammation and metabolism.BMC genomics · 2024Article
- Cellular Context Dictates the Suppression or Augmentation of Triple-Negative Mammary Tumor Metastasis by NLRX1.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study.3 Biotech · 2023Article
- NLRX1 functions as a tumor suppressor in Pan02 pancreatic cancer cells.Frontiers in oncology · 2023Article
- Multifaceted roles and regulation of nucleotide-binding oligomerization domain containing proteins.Frontiers in immunology · 2023Review
- Targeting the NLRP3 inflammasome in cardiovascular diseases.Pharmacology & therapeutics · 2022Review
- Review
- Bacterial subversion of NLR-mediated immune responses.Frontiers in immunology · 2022Review
- TLR2 Potentiates SR-Marco-Mediated Neuroinflammation by Interacting with the SRCR Domain.Molecular neurobiology · 2021Article
- NOD1-Targeted Immunonutrition Approaches: On the Way from Disease to Health.Biomedicines · 2021Review
- NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2021Review
- Evolution of Our Understanding of XIAP Deficiency.Frontiers in pediatrics · 2021Review
- NOD2/RIG-I ActivatingFrontiers in immunology · 2020Article
- NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer.Bioscience reports · 2019Review
- NOD2 Expression in Intestinal Epithelial Cells Protects Toward the Development of Inflammation and Associated Carcinogenesis.Cellular and molecular gastroenterology and hepatology · 2019Review
- Subinhibitory concentrations of Honokiol reduce α-Hemolysin (Hla) secretion byEmerging microbes & infections · 2019Article
- From autoinflammation to autoimmunity: old and recent findings.Clinical rheumatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptors (TLRs) and the nucleotide-binding domain, leucine rich repeat containing family (or Nod-like receptors, NLRs) are two important families of microbial sensors that are membrane-associated and cytosolic molecules, respectively. The Nod proteins Nod1 and Nod2 are two NLR family members that trigger immune defense in response to bacterial peptidoglycan. Nod proteins fight off bacterial infections by stimulating proinflammatory signaling and cytokine networks and by inducing antimicrobial effectors, such as nitric oxide and antimicrobial peptides. Nod1 is also critically implicated in shaping adaptive immune responses towards bacterial-derived constituents. In addition, recent evidence has demonstrated that mutations in Nod1 and Nod2 are associated with a number of human inflammatory disorders, including Crohn's disease, Blau syndrome, early-onset sarcoidosis, and atopic diseases. Together, Nod1 and Nod2 represent central players in the control of immune responses to bacterial infections and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.